 Neil Aggarwal
Concepts (270)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Outpatients | 4 | 2023 | 326 | 2.050 |
Why?
| | Oxygen | 6 | 2023 | 854 | 1.760 |
Why?
| | Acute Lung Injury | 11 | 2015 | 299 | 1.310 |
Why?
| | Macrophages, Alveolar | 5 | 2016 | 348 | 1.280 |
Why?
| | Pneumonia | 6 | 2018 | 568 | 0.980 |
Why?
| | T-Lymphocytes, Regulatory | 5 | 2015 | 339 | 0.910 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 6 | 2021 | 93 | 0.740 |
Why?
| | Positive-Pressure Respiration | 1 | 2018 | 68 | 0.580 |
Why?
| | Phagocytes | 1 | 2018 | 90 | 0.570 |
Why?
| | Oxygen Inhalation Therapy | 2 | 2014 | 129 | 0.530 |
Why?
| | Lung | 12 | 2018 | 3561 | 0.510 |
Why?
| | Leukocytes, Mononuclear | 1 | 2018 | 493 | 0.490 |
Why?
| | Smoke | 1 | 2016 | 123 | 0.490 |
Why?
| | Receptor, Adenosine A2A | 1 | 2013 | 20 | 0.430 |
Why?
| | Lipopolysaccharides | 9 | 2015 | 823 | 0.410 |
Why?
| | Immunity, Innate | 1 | 2018 | 720 | 0.400 |
Why?
| | Lung Injury | 2 | 2011 | 198 | 0.360 |
Why?
| | Mice, Inbred C57BL | 15 | 2016 | 4694 | 0.350 |
Why?
| | Hydroxychloroquine | 2 | 2020 | 54 | 0.350 |
Why?
| | Bacteria | 1 | 2016 | 725 | 0.350 |
Why?
| | Smoking | 2 | 2016 | 1383 | 0.340 |
Why?
| | Macrophages | 1 | 2016 | 1263 | 0.330 |
Why?
| | Research Report | 2 | 2021 | 75 | 0.320 |
Why?
| | Respiratory Insufficiency | 2 | 2023 | 290 | 0.320 |
Why?
| | Bronchoalveolar Lavage Fluid | 7 | 2013 | 590 | 0.310 |
Why?
| | Flow Cytometry | 3 | 2018 | 1083 | 0.300 |
Why?
| | Epithelial Cells | 4 | 2016 | 951 | 0.300 |
Why?
| | Wound Healing | 1 | 2009 | 258 | 0.290 |
Why?
| | Mice | 14 | 2018 | 14871 | 0.280 |
Why?
| | Inflammation Mediators | 4 | 2016 | 477 | 0.280 |
Why?
| | Adult | 13 | 2023 | 30552 | 0.280 |
Why?
| | Mice, Knockout | 8 | 2015 | 2570 | 0.280 |
Why?
| | Hospitalization | 4 | 2022 | 1752 | 0.280 |
Why?
| | Antiviral Agents | 2 | 2023 | 645 | 0.270 |
Why?
| | Immunophenotyping | 2 | 2018 | 274 | 0.260 |
Why?
| | Vaccination | 1 | 2014 | 1204 | 0.260 |
Why?
| | Carotid Artery, Internal | 1 | 2006 | 36 | 0.260 |
Why?
| | Carotid Artery Diseases | 1 | 2006 | 57 | 0.250 |
Why?
| | Humans | 35 | 2023 | 114696 | 0.250 |
Why?
| | Phagocytosis | 2 | 2018 | 350 | 0.240 |
Why?
| | Animals | 18 | 2018 | 31708 | 0.240 |
Why?
| | Intracranial Aneurysm | 1 | 2006 | 91 | 0.240 |
Why?
| | Antibodies, Neutralizing | 2 | 2022 | 222 | 0.230 |
Why?
| | Biomedical Research | 2 | 2021 | 585 | 0.230 |
Why?
| | Lung Diseases | 2 | 2021 | 701 | 0.230 |
Why?
| | Gene Expression Profiling | 1 | 2009 | 1518 | 0.220 |
Why?
| | Public-Private Sector Partnerships | 2 | 2021 | 43 | 0.210 |
Why?
| | Hypoxia | 3 | 2014 | 958 | 0.200 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2006 | 209 | 0.200 |
Why?
| | Ritonavir | 1 | 2023 | 71 | 0.200 |
Why?
| | Pulmonary Circulation | 2 | 2021 | 407 | 0.200 |
Why?
| | Antibodies, Monoclonal | 3 | 2022 | 1262 | 0.200 |
Why?
| | Cytokines | 3 | 2016 | 1841 | 0.190 |
Why?
| | Male | 22 | 2023 | 55604 | 0.190 |
Why?
| | Cell Membrane Permeability | 2 | 2012 | 83 | 0.180 |
Why?
| | Education | 1 | 2021 | 95 | 0.180 |
Why?
| | Pulmonary Alveoli | 3 | 2015 | 373 | 0.170 |
Why?
| | Tidal Volume | 2 | 2018 | 75 | 0.170 |
Why?
| | Neutrophils | 4 | 2015 | 1176 | 0.170 |
Why?
| | Triglycerides | 2 | 2013 | 467 | 0.170 |
Why?
| | Antibodies | 1 | 2021 | 371 | 0.170 |
Why?
| | Ventricular Function, Right | 1 | 2021 | 250 | 0.160 |
Why?
| | Financing, Government | 1 | 2019 | 40 | 0.160 |
Why?
| | Serum Bactericidal Test | 1 | 2018 | 1 | 0.160 |
Why?
| | Pandemics | 3 | 2022 | 1320 | 0.160 |
Why?
| | Rare Diseases | 1 | 2019 | 89 | 0.150 |
Why?
| | Interinstitutional Relations | 1 | 2018 | 54 | 0.150 |
Why?
| | Partial Pressure | 1 | 2018 | 30 | 0.150 |
Why?
| | Vascular Diseases | 1 | 2021 | 230 | 0.150 |
Why?
| | APACHE | 1 | 2018 | 58 | 0.150 |
Why?
| | Endothelial Cells | 2 | 2016 | 687 | 0.150 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2018 | 72 | 0.150 |
Why?
| | Blood Gas Analysis | 1 | 2018 | 72 | 0.150 |
Why?
| | Streptococcus | 1 | 2018 | 22 | 0.150 |
Why?
| | Precision Medicine | 1 | 2021 | 337 | 0.150 |
Why?
| | Disease Models, Animal | 5 | 2015 | 3535 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 250 | 0.140 |
Why?
| | Macrophage Activation | 1 | 2018 | 164 | 0.140 |
Why?
| | Goals | 1 | 2018 | 147 | 0.140 |
Why?
| | Cell Separation | 1 | 2018 | 291 | 0.140 |
Why?
| | Adoptive Transfer | 3 | 2015 | 195 | 0.140 |
Why?
| | Soot | 1 | 2016 | 16 | 0.130 |
Why?
| | Disease Susceptibility | 1 | 2018 | 316 | 0.130 |
Why?
| | Critical Illness | 2 | 2018 | 646 | 0.130 |
Why?
| | Lung Transplantation | 1 | 2018 | 246 | 0.130 |
Why?
| | Research | 1 | 2019 | 394 | 0.130 |
Why?
| | Chemokines | 2 | 2015 | 216 | 0.130 |
Why?
| | Leukocytosis | 1 | 2015 | 34 | 0.130 |
Why?
| | Aged | 8 | 2022 | 19074 | 0.130 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 338 | 0.120 |
Why?
| | DNA Modification Methylases | 1 | 2015 | 14 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 330 | 0.120 |
Why?
| | Tissue and Organ Procurement | 1 | 2018 | 228 | 0.120 |
Why?
| | Muscular Atrophy | 2 | 2015 | 78 | 0.120 |
Why?
| | Wasting Syndrome | 1 | 2015 | 11 | 0.120 |
Why?
| | Epithelium | 1 | 2016 | 295 | 0.120 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2012 | 157 | 0.120 |
Why?
| | Air Pollution, Indoor | 1 | 2016 | 108 | 0.120 |
Why?
| | Societies, Medical | 1 | 2018 | 664 | 0.120 |
Why?
| | Particulate Matter | 1 | 2016 | 185 | 0.120 |
Why?
| | Ubiquitin-Protein Ligases | 2 | 2015 | 139 | 0.120 |
Why?
| | Critical Care | 1 | 2018 | 476 | 0.120 |
Why?
| | Interleukin-10 | 2 | 2014 | 299 | 0.120 |
Why?
| | Lipoprotein Lipase | 2 | 2013 | 54 | 0.120 |
Why?
| | Intensive Care Units | 1 | 2018 | 617 | 0.110 |
Why?
| | Muscle Proteins | 2 | 2015 | 210 | 0.110 |
Why?
| | Azacitidine | 1 | 2015 | 129 | 0.110 |
Why?
| | Cells, Cultured | 4 | 2016 | 3886 | 0.110 |
Why?
| | Osteomyelitis | 1 | 2015 | 105 | 0.110 |
Why?
| | Lipoproteins | 2 | 2013 | 159 | 0.110 |
Why?
| | United States | 8 | 2021 | 12185 | 0.110 |
Why?
| | Bacteremia | 1 | 2015 | 160 | 0.110 |
Why?
| | Middle Aged | 8 | 2023 | 26737 | 0.110 |
Why?
| | Colorado | 1 | 2023 | 4099 | 0.110 |
Why?
| | Phenethylamines | 1 | 2013 | 18 | 0.110 |
Why?
| | Air Pollutants | 1 | 2016 | 242 | 0.110 |
Why?
| | Adenosine A2 Receptor Agonists | 1 | 2013 | 19 | 0.110 |
Why?
| | Forkhead Transcription Factors | 2 | 2015 | 170 | 0.110 |
Why?
| | Physical Conditioning, Animal | 1 | 2015 | 194 | 0.100 |
Why?
| | Gene Knockout Techniques | 1 | 2013 | 98 | 0.100 |
Why?
| | Sepsis | 1 | 2018 | 509 | 0.100 |
Why?
| | Adaptive Clinical Trials as Topic | 2 | 2022 | 19 | 0.100 |
Why?
| | Aquaporin 5 | 1 | 2012 | 2 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 923 | 0.100 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2016 | 916 | 0.100 |
Why?
| | Time Factors | 5 | 2016 | 6116 | 0.100 |
Why?
| | Enzyme Inhibitors | 1 | 2015 | 750 | 0.100 |
Why?
| | Retrospective Studies | 3 | 2023 | 12554 | 0.100 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 2 | 1 | 2011 | 1 | 0.090 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2387 | 0.090 |
Why?
| | Adenosine | 1 | 2013 | 203 | 0.090 |
Why?
| | Exercise Therapy | 1 | 2015 | 352 | 0.090 |
Why?
| | Staphylococcal Infections | 1 | 2015 | 340 | 0.090 |
Why?
| | Capillary Permeability | 1 | 2011 | 139 | 0.090 |
Why?
| | Treatment Outcome | 5 | 2023 | 9088 | 0.090 |
Why?
| | Aftercare | 2 | 2023 | 186 | 0.090 |
Why?
| | Biomarkers | 2 | 2018 | 3408 | 0.090 |
Why?
| | Treatment Failure | 2 | 2022 | 331 | 0.090 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2540 | 0.090 |
Why?
| | HIV-1 | 1 | 2016 | 768 | 0.090 |
Why?
| | Hypertension, Pulmonary | 1 | 2021 | 1729 | 0.090 |
Why?
| | Genes, RAG-1 | 1 | 2009 | 11 | 0.090 |
Why?
| | Microtubules | 1 | 2012 | 237 | 0.090 |
Why?
| | Leukocyte Reduction Procedures | 1 | 2009 | 25 | 0.080 |
Why?
| | Monocytes | 1 | 2012 | 504 | 0.080 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2009 | 66 | 0.080 |
Why?
| | Leukocyte Count | 1 | 2009 | 293 | 0.080 |
Why?
| | Heart Failure | 1 | 2021 | 1945 | 0.080 |
Why?
| | Muscle, Skeletal | 2 | 2015 | 1473 | 0.080 |
Why?
| | Cluster Analysis | 1 | 2009 | 455 | 0.080 |
Why?
| | Gene Regulatory Networks | 1 | 2009 | 228 | 0.070 |
Why?
| | Female | 9 | 2023 | 59518 | 0.070 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2011 | 196 | 0.070 |
Why?
| | Interleukin-6 | 1 | 2011 | 676 | 0.070 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2009 | 740 | 0.070 |
Why?
| | Adipose Tissue | 1 | 2011 | 545 | 0.070 |
Why?
| | T-Lymphocyte Subsets | 1 | 2009 | 383 | 0.070 |
Why?
| | Patient Discharge | 2 | 2023 | 772 | 0.070 |
Why?
| | Homeodomain Proteins | 3 | 2015 | 463 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 2 | 2006 | 2286 | 0.060 |
Why?
| | Gene Expression Regulation | 2 | 2012 | 2320 | 0.060 |
Why?
| | Receptors, CXCR4 | 2 | 2016 | 78 | 0.060 |
Why?
| | Sensitivity and Specificity | 3 | 2018 | 1693 | 0.060 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2009 | 959 | 0.060 |
Why?
| | Tripartite Motif Proteins | 2 | 2015 | 30 | 0.060 |
Why?
| | Nucleocapsid | 1 | 2022 | 17 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2022 | 59 | 0.050 |
Why?
| | Angiopoietins | 2 | 2013 | 12 | 0.050 |
Why?
| | Cell Line, Transformed | 2 | 2012 | 133 | 0.050 |
Why?
| | HIV Infections | 1 | 2016 | 2469 | 0.050 |
Why?
| | Epigenomics | 1 | 2022 | 101 | 0.050 |
Why?
| | Phenotype | 2 | 2022 | 2796 | 0.050 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2002 | 41 | 0.050 |
Why?
| | Prospective Studies | 3 | 2023 | 6220 | 0.050 |
Why?
| | Blotting, Western | 2 | 2016 | 1147 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 249 | 0.050 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2021 | 106 | 0.050 |
Why?
| | Cohort Studies | 2 | 2023 | 4895 | 0.050 |
Why?
| | Random Allocation | 2 | 2012 | 335 | 0.050 |
Why?
| | User-Computer Interface | 1 | 2002 | 140 | 0.050 |
Why?
| | Review Literature as Topic | 1 | 2021 | 61 | 0.050 |
Why?
| | Macrophages, Peritoneal | 2 | 2012 | 93 | 0.050 |
Why?
| | Drug Discovery | 1 | 2021 | 123 | 0.040 |
Why?
| | Antimalarials | 1 | 2020 | 24 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2022 | 329 | 0.040 |
Why?
| | Bronchoscopy | 1 | 2002 | 245 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2020 | 258 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2023 | 520 | 0.040 |
Why?
| | Airway Obstruction | 1 | 2002 | 168 | 0.040 |
Why?
| | Netherlands | 1 | 2018 | 64 | 0.040 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2021 | 217 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2022 | 520 | 0.040 |
Why?
| | Inflammation | 3 | 2015 | 2480 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2022 | 932 | 0.040 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2002 | 685 | 0.040 |
Why?
| | Risk Factors | 2 | 2022 | 8632 | 0.040 |
Why?
| | Computational Biology | 1 | 2021 | 530 | 0.040 |
Why?
| | ROC Curve | 1 | 2018 | 442 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2018 | 195 | 0.030 |
Why?
| | Bacterial Infections | 1 | 2018 | 218 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2020 | 1842 | 0.030 |
Why?
| | Graft Survival | 1 | 2018 | 446 | 0.030 |
Why?
| | Virus Diseases | 1 | 2018 | 195 | 0.030 |
Why?
| | Cooperative Behavior | 1 | 2018 | 381 | 0.030 |
Why?
| | Cell Count | 1 | 2016 | 303 | 0.030 |
Why?
| | Receptors, Granulocyte Colony-Stimulating Factor | 1 | 2015 | 1 | 0.030 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2016 | 154 | 0.030 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 157 | 0.030 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2015 | 71 | 0.030 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2015 | 130 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2016 | 304 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2006 | 3053 | 0.030 |
Why?
| | Cadherins | 1 | 2016 | 175 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 2016 | 522 | 0.030 |
Why?
| | Environmental Monitoring | 1 | 2016 | 254 | 0.030 |
Why?
| | Sputum | 1 | 2016 | 285 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1342 | 0.030 |
Why?
| | Cell Lineage | 1 | 2016 | 309 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2015 | 195 | 0.030 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2015 | 139 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2016 | 295 | 0.030 |
Why?
| | Adipose Tissue, White | 1 | 2013 | 27 | 0.030 |
Why?
| | Cell Survival | 1 | 2016 | 1021 | 0.030 |
Why?
| | Benzylamines | 1 | 2012 | 39 | 0.030 |
Why?
| | Adipose Tissue, Brown | 1 | 2013 | 43 | 0.030 |
Why?
| | Mice, Congenic | 1 | 2012 | 21 | 0.030 |
Why?
| | B7-2 Antigen | 1 | 2012 | 25 | 0.030 |
Why?
| | Heterocyclic Compounds | 1 | 2012 | 18 | 0.030 |
Why?
| | Chemokine CXCL12 | 1 | 2012 | 74 | 0.030 |
Why?
| | RING Finger Domains | 1 | 2012 | 2 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 4410 | 0.020 |
Why?
| | Quality of Life | 1 | 2023 | 2353 | 0.020 |
Why?
| | Diet, Atherogenic | 1 | 2011 | 6 | 0.020 |
Why?
| | Chylomicrons | 1 | 2011 | 6 | 0.020 |
Why?
| | Ventilators, Mechanical | 1 | 2011 | 52 | 0.020 |
Why?
| | Lipoproteins, VLDL | 1 | 2011 | 21 | 0.020 |
Why?
| | Myofibroblasts | 1 | 2012 | 116 | 0.020 |
Why?
| | Cyclic GMP | 1 | 2011 | 80 | 0.020 |
Why?
| | Gene Expression | 1 | 2016 | 1421 | 0.020 |
Why?
| | Ventilator-Induced Lung Injury | 1 | 2011 | 49 | 0.020 |
Why?
| | Cyclic AMP | 1 | 2011 | 227 | 0.020 |
Why?
| | Adenoviridae | 1 | 2011 | 184 | 0.020 |
Why?
| | Obesity | 1 | 2022 | 2508 | 0.020 |
Why?
| | Motor Activity | 1 | 2015 | 640 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2021 | 1727 | 0.020 |
Why?
| | Down-Regulation | 1 | 2012 | 594 | 0.020 |
Why?
| | Risk Assessment | 1 | 2018 | 2968 | 0.020 |
Why?
| | Trachea | 1 | 2011 | 224 | 0.020 |
Why?
| | Muscle Strength | 1 | 2012 | 271 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2011 | 535 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2011 | 498 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2012 | 1430 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2018 | 2128 | 0.020 |
Why?
| | Fibroblasts | 1 | 2012 | 838 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2011 | 529 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1629 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2018 | 6347 | 0.020 |
Why?
| | Cell Line | 1 | 2012 | 2637 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1481 | 0.020 |
Why?
| | Survival Rate | 1 | 2009 | 1644 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2012 | 2187 | 0.020 |
Why?
| | Proteins | 1 | 2011 | 908 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2009 | 1214 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2011 | 2553 | 0.010 |
Why?
| | Bronchography | 1 | 2002 | 9 | 0.010 |
Why?
| | Blood Glucose | 1 | 2011 | 1828 | 0.010 |
Why?
| | Tracheal Stenosis | 1 | 2002 | 24 | 0.010 |
Why?
| | Insulin | 1 | 2011 | 2080 | 0.010 |
Why?
| | Observer Variation | 1 | 2002 | 296 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 4515 | 0.010 |
Why?
|
|
Aggarwal's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|